AZ
QNCX icon

Alpha Zero’s Quince Therapeutics QNCX Stock Holding History

Alpha Zero’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-65
Closed -$1.32K – 109
2026
Q1 		$1.32K Buy
+65
New +$13K ﹤0.01% 79

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Alpha Zero's QNCX Position: Q2 2026 in Review

Alpha Zero sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 65 shares — an estimated $1.32K sold.

Alpha Zero first reported a position in QNCX in Q1 2026 and held it in 1 quarter. The position peaked at $1.32K in Q1 2026. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Alpha Zero reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Alpha Zero sold 65 Quince Therapeutics shares in Q2 2026, an estimated $1.32K.
  • Alpha Zero first reported a position in Quince Therapeutics in Q1 2026 and held it in 1 quarter.
  • Alpha Zero's Quince Therapeutics position peaked at $1.32K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Alpha Zero's 13F filing for Q2 2026, filed 20 Jul 2026.